Terry Bowlin, Ph.D.

Dr. Bowlin currently serves as President & CEO of Microbiotix, Inc., providing strategic management, operational and anti-infective R&D oversight, which includes medical/therapeutic solutions for biological threats. He was previously VP of Research at BioChem Pharma, focused on anti-viral and oncology R&D, and Director of Immunology at Marion Merrell Dow. He has extensive experience in anti-infective research, preclinical and clinical development, including regulatory. Dr. Bowlin has taken over a dozen novel compounds from bench discovery through preclinical development, successful IND regulatory approval, and into clinical trials. He has long standing collaborations and joint funding with NIAID and DoD regarding NIAID Category A, B and C Priority Pathogens, multidrug-resistant pathogens, and emerging bio-threats and biodefense. Dr. Bowlin has served on multiple research and development committees and global development portfolio management committees (e.g., Marion Merrell Dow, BioChem Pharma).